Drug Profile
Research programme: bladder diseases therapeutics - TARIS Biomedical/AstraZeneca
Alternative Names: TD-210Latest Information Update: 15 Jul 2021
Price :
$50
*
At a glance
- Originator AstraZeneca; TARIS Biomedical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bladder cancer; Overactive bladder
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bladder-cancer in USA (Intravesicular, Controlled release)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Overactive bladder in USA (Intravesicular)
- 16 Oct 2013 Preclinical trials in Overactive bladder in USA (Intravesicular) after October 2013 (TARIS pipeline, December 2013)